http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#Head http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#provenance http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#pubinfo http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion http://purl.obolibrary.org/obo/DOID_9253 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9253 http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01268 http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association http://www.w3.org/2000/01/rdf-schema#label sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 1 1 the treatment of advanced renal cell carcinoma rcc 1 2 the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 1 3 the treatment of progressive well differentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 1 4 sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate sutent is indicated for the treatment of advanced renal cell carcinoma sutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy sutent is indicated for the treatment of progressive well differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01268 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#provenance http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#pubinfo http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig http://purl.org/nanopub/x/hasSignature W7evpAoZitylKf6XLlyxemxu4Yj4Qb2Uh7K4Elax2iDSZeCSjR6xY2Dr2RFon1dO65mpnh6bk2j4A7y+IaO4hA3fqOx8ZRyeF58QZkDhgMjxuGKS+Zw0LCAibOCvzFyc5tvJfbyQyQMROZv26BZc4V/sDnsWfDsmKaVeeruddfg= http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://purl.org/dc/terms/created 2021-07-03T11:32:50.622+02:00 http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs